Missing Script

Get updates

Evidence Explorer · MS-N308 · Mineral–peptide complex · Supportive care · Appraised 11 November 2026

A 42-person single-blind randomized trial reported improvement in established oral mucositis with a zinc‑L‑carnosine mouthwash, but design imbalances and small size limit confidence.

Evidence at a glance

  • Evidence label: Promising small randomized treatment trial
  • Benefit: Moderate/severe mucositis in the test group fell from 61% at baseline to 28% at day 15 and 14% at day 30, while severe mucositis increased in the control group.
  • Certainty: Low: single-blind, 42 participants, unequal control regimen and mixed radiation/chemotherapy settings.
  • Risk: Local irritation or intolerance is possible; swallowed zinc can cause nausea, copper deficiency with prolonged high exposure and medicine interactions.
  • Goal: Treatment of established oral mucositis; not cancer control.

What was studied

Design: Forty-two cancer patients with oral mucositis were randomized to Hepilor zinc‑L‑carnosine mouthwash (22) or water plus sodium bicarbonate rinses (20). The test regimen was 10 mL undiluted, four rinses daily for three minutes over 30 days; control was two one-minute rinses daily.

Results: In the test group, moderate/severe mucositis decreased from 61% at baseline to 28% at day 15 and 14% at day 30; analgesic use fell from 63% to 14% and then 0%. Control-group severe mucositis and analgesic use increased. The unequal rinse frequency and duration can exaggerate a product effect.

Related evidence: Other zinc‑L‑carnosine studies in hematopoietic stem-cell transplantation use different preventive regimens and populations and should not be counted as replications of this treatment trial.

What this evidence cannot establish

This study does not establish superiority over an attention-matched active oral-care protocol or effectiveness in a single specific cancer treatment.

Mucositis improvement does not imply tumor response or safer continuation of therapy without clinical review.

Safety and practical context

Use only under the treating team’s oral-care protocol. Do not assume a commercial mouthwash should be swallowed unless the studied instructions and clinician explicitly say so.

Account for total zinc exposure. Prolonged high systemic intake can reduce copper absorption and zinc can interact with quinolone or tetracycline antibiotics and penicillamine.

Questions for the care team

  • Is the goal prevention or treatment of established mucositis?
  • Does the comparison control for rinse frequency and oral-care attention?
  • How much zinc is absorbed or swallowed, and should copper or medicine timing be reviewed?

Sources and identifiers

Funding and conflicts: The 2026 abstract did not report complete funding or conflict details; Hepilor is a named commercial formulation.

Source access: Original reports, abstracts/full text where available, registries and authoritative safety sources checked 11 November 2026. The 2026 study was appraised from its abstract; full-text adverse-event and allocation details were not independently verified.

This educational evidence record is not a personal treatment recommendation. Symptom or toxicity findings do not establish tumor response, delayed recurrence or longer survival; laboratory and animal findings are not proof of clinical benefit.